Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Melanoma 2 Colorectal Neoplasms 2 Advanced Solid Tumors 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor, Unspecified, Adult 1 Prostatic Neoplasms, Castration-Resistant 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Breast Neoplasms 1

Interventions

Carboplatin 171 Paclitaxel 129 Radiotherapy 119 Cisplatin 109 Docetaxel 93 Gemcitabine 81 Erlotinib Hydrochloride 80 Pemetrexed 78 Bevacizumab 56 Etoposide 41 pembrolizumab 36 Gefitinib 32 Vinorelbine 31 Topotecan 30 Surveys and Questionnaires 29 Irinotecan 28 Radiosurgery 21 Nivolumab 20 Drug Therapy 20 Magnetic Resonance Spectroscopy 18 Cetuximab 18 durvalumab 17 Early Intervention, Educational 17 Blood Specimen Collection 17 Surgical Procedures, Operative 16 Cyclophosphamide 16 Celecoxib 15 Ipilimumab 14 Immunohistochemistry 14 Filgrastim 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lung Neoplasms × zimberelimab × Clear all

NCT04262856 2025-08-26

ARC-7

Arcus Biosciences, Inc.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡